| Dr Richard F Golden, MD | |
|
1001 Briggs Rd, Suite 250, Mount Laurel, NJ 08054-4100 | |
| (856) 866-7466 | |
| (856) 866-9088 |
| Full Name | Dr Richard F Golden |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 36 Years |
| Location | 1001 Briggs Rd, Mount Laurel, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083666879 | NPI | - | NPPES |
| 7123205 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | MA064851 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virtua West Jersey Hospitals | Voorhees, NJ | Hospital |
| Virtua Memorial Hospital Of Burlington County | Mount holly, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Virtua Medical Group, Pa | 9830222397 | 1226 |
News Archive
When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication Pioglitazone can prevent the long term effects of maternal obesity on offspring.
When University of Wisconsin-Madison researchers succeeded in reprogramming skin cells to behave like embryonic stem cells, they also began to redefine the political and ethical dynamics of the stem-cell debate, a leading bioethicist says. R. Alta Charo, a UW-Madison professor of law and bioethics, says the scientific finding could have far-reaching effects on the social dimensions of the ongoing controversy over embryonic stem cell research.
› Verified 1 days ago
| Entity Name | Virtua Medical Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649226515 PECOS PAC ID: 9830222397 Enrollment ID: O20100804000338 |
News Archive
When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication Pioglitazone can prevent the long term effects of maternal obesity on offspring.
When University of Wisconsin-Madison researchers succeeded in reprogramming skin cells to behave like embryonic stem cells, they also began to redefine the political and ethical dynamics of the stem-cell debate, a leading bioethicist says. R. Alta Charo, a UW-Madison professor of law and bioethics, says the scientific finding could have far-reaching effects on the social dimensions of the ongoing controversy over embryonic stem cell research.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Richard F Golden, MD 204 Sunny Jim Dr, Medford, NJ 08055-9250 Ph: (609) 714-0118 | Dr Richard F Golden, MD 1001 Briggs Rd, Suite 250, Mount Laurel, NJ 08054-4100 Ph: (856) 866-7466 |
News Archive
When The Cancer Genome Atlas launched its massively collaborative approach to organ-by-organ genomic analysis of cancers, the brain had both the benefit, and the challenge, of going first.
Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs, today jointly announced the results from their Phase 1 combination trial of belinostat (Beleodaq) with the CHOP (Cyclophosphamide, Hydroxyl-doxorubicin; Vincristine, and Prednisone) chemotherapy regimen as first-line treatment for newly diagnosed peripheral T-cell lymphoma (PTCL).
In a study to be presented today at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting -, in Dallas, Texas, researchers will report findings that show that short therapy with the anti-diabetic medication Pioglitazone can prevent the long term effects of maternal obesity on offspring.
When University of Wisconsin-Madison researchers succeeded in reprogramming skin cells to behave like embryonic stem cells, they also began to redefine the political and ethical dynamics of the stem-cell debate, a leading bioethicist says. R. Alta Charo, a UW-Madison professor of law and bioethics, says the scientific finding could have far-reaching effects on the social dimensions of the ongoing controversy over embryonic stem cell research.
› Verified 1 days ago
Foad I. Abandeh, MBBS Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1001 Briggs Rd Ste 250, Mount Laurel, NJ 08054 Phone: 856-866-7466 Fax: 856-866-9088 | |
Dr. Sherin Mary Thomas Meledathu, D.O. Infectious Disease Medicare: Medicare Enrolled Practice Location: 1001 Briggs Rd Ste 250, Mount Laurel, NJ 08054 Phone: 856-866-7466 Fax: 856-866-9088 | |
Yize Richard Wang, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 501 Fellowship Rd, Suite 101, Mount Laurel, NJ 08054 Phone: 856-642-2133 Fax: 856-642-2134 | |
Dr. Joshua Peter Desipio, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 501 Fellowship Rd, Suite 101, Mount Laurel, NJ 08054 Phone: 856-963-3572 Fax: 856-338-9211 | |
Dr. Jeffrey M Sumerson, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 1001 Briggs Rd, Suite 250, Mount Laurel, NJ 08054 Phone: 856-866-7466 Fax: 856-866-9088 | |
Dr. Thanuja K Hamilton, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 204 Ark Road, Suite 206 Lmc I, Mount Laurel, NJ 08054 Phone: 856-778-4640 Fax: 856-778-8862 |